Altogether, FABP3 appears to be involved in αSyn uptake into dopaminergic neurons and to enhance the propagation of αSyn aggregates, suggesting FABP3 as a potential therapeutic target for synucleinopathies. This evidence concerns the gene FABP3 and synucleinopathy.